Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1966 3
1971 1
1972 3
1975 1
1982 1
1984 1
1985 1
1987 1
1989 1
1995 1
1996 2
1997 1
1998 2
2004 1
2005 2
2006 4
2007 4
2008 4
2009 1
2010 3
2011 4
2012 6
2013 6
2014 6
2015 4
2016 6
2017 5
2018 12
2019 3
2020 3
2021 6
2022 6
2023 3
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

98 results

Results by year

Filters applied: . Clear all
Page 1
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
Mateo J, Carreira S, Sandhu S, Miranda S, Mossop H, Perez-Lopez R, Nava Rodrigues D, Robinson D, Omlin A, Tunariu N, Boysen G, Porta N, Flohr P, Gillman A, Figueiredo I, Paulding C, Seed G, Jain S, Ralph C, Protheroe A, Hussain S, Jones R, Elliott T, McGovern U, Bianchini D, Goodall J, Zafeiriou Z, Williamson CT, Ferraldeschi R, Riisnaes R, Ebbs B, Fowler G, Roda D, Yuan W, Wu YM, Cao X, Brough R, Pemberton H, A'Hern R, Swain A, Kunju LP, Eeles R, Attard G, Lord CJ, Ashworth A, Rubin MA, Knudsen KE, Feng FY, Chinnaiyan AM, Hall E, de Bono JS. Mateo J, et al. Among authors: brough r. N Engl J Med. 2015 Oct 29;373(18):1697-708. doi: 10.1056/NEJMoa1506859. N Engl J Med. 2015. PMID: 26510020 Free PMC article. Clinical Trial.
Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance.
Zatreanu D, Robinson HMR, Alkhatib O, Boursier M, Finch H, Geo L, Grande D, Grinkevich V, Heald RA, Langdon S, Majithiya J, McWhirter C, Martin NMB, Moore S, Neves J, Rajendra E, Ranzani M, Schaedler T, Stockley M, Wiggins K, Brough R, Sridhar S, Gulati A, Shao N, Badder LM, Novo D, Knight EG, Marlow R, Haider S, Callen E, Hewitt G, Schimmel J, Prevo R, Alli C, Ferdinand A, Bell C, Blencowe P, Bot C, Calder M, Charles M, Curry J, Ekwuru T, Ewings K, Krajewski W, MacDonald E, McCarron H, Pang L, Pedder C, Rigoreau L, Swarbrick M, Wheatley E, Willis S, Wong AC, Nussenzweig A, Tijsterman M, Tutt A, Boulton SJ, Higgins GS, Pettitt SJ, Smith GCM, Lord CJ. Zatreanu D, et al. Among authors: brough r. Nat Commun. 2021 Jun 17;12(1):3636. doi: 10.1038/s41467-021-23463-8. Nat Commun. 2021. PMID: 34140467 Free PMC article.
The shieldin complex mediates 53BP1-dependent DNA repair.
Noordermeer SM, Adam S, Setiaputra D, Barazas M, Pettitt SJ, Ling AK, Olivieri M, Álvarez-Quilón A, Moatti N, Zimmermann M, Annunziato S, Krastev DB, Song F, Brandsma I, Frankum J, Brough R, Sherker A, Landry S, Szilard RK, Munro MM, McEwan A, Goullet de Rugy T, Lin ZY, Hart T, Moffat J, Gingras AC, Martin A, van Attikum H, Jonkers J, Lord CJ, Rottenberg S, Durocher D. Noordermeer SM, et al. Among authors: brough r. Nature. 2018 Aug;560(7716):117-121. doi: 10.1038/s41586-018-0340-7. Epub 2018 Jul 18. Nature. 2018. PMID: 30022168 Free PMC article.
Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance.
Serra V, Wang AT, Castroviejo-Bermejo M, Polanska UM, Palafox M, Herencia-Ropero A, Jones GN, Lai Z, Armenia J, Michopoulos F, Llop-Guevara A, Brough R, Gulati A, Pettitt SJ, Bulusu KC, Nikkilä J, Wilson Z, Hughes A, Wijnhoven PWG, Ahmed A, Bruna A, Gris-Oliver A, Guzman M, Rodríguez O, Grueso J, Arribas J, Cortés J, Saura C, Lau A, Critchlow S, Dougherty B, Caldas C, Mills GB, Barrett JC, Forment JV, Cadogan E, Lord CJ, Cruz C, Balmaña J, O'Connor MJ. Serra V, et al. Among authors: brough r. Clin Cancer Res. 2022 Oct 14;28(20):4536-4550. doi: 10.1158/1078-0432.CCR-22-0568. Clin Cancer Res. 2022. PMID: 35921524 Free PMC article.
Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.
Bajrami I, Frankum JR, Konde A, Miller RE, Rehman FL, Brough R, Campbell J, Sims D, Rafiq R, Hooper S, Chen L, Kozarewa I, Assiotis I, Fenwick K, Natrajan R, Lord CJ, Ashworth A. Bajrami I, et al. Among authors: brough r. Cancer Res. 2014 Jan 1;74(1):287-97. doi: 10.1158/0008-5472.CAN-13-2541. Epub 2013 Nov 15. Cancer Res. 2014. PMID: 24240700 Free PMC article.
MND1 and PSMC3IP control PARP inhibitor sensitivity in mitotic cells.
Zelceski A, Francica P, Lingg L, Mutlu M, Stok C, Liptay M, Alexander J, Baxter JS, Brough R, Gulati A, Haider S, Raghunandan M, Song F, Sridhar S, Forment JV, O'Connor MJ, Davies BR, van Vugt MATM, Krastev DB, Pettitt SJ, Tutt ANJ, Rottenberg S, Lord CJ. Zelceski A, et al. Among authors: brough r. Cell Rep. 2023 May 30;42(5):112484. doi: 10.1016/j.celrep.2023.112484. Epub 2023 May 9. Cell Rep. 2023. PMID: 37163373 Free article.
A HUWE1 defect causes PARP inhibitor resistance by modulating the BRCA1-∆11q splice variant.
Pettitt SJ, Shao N, Zatreanu D, Frankum J, Bajrami I, Brough R, Krastev DB, Roumeliotis TI, Choudhary JS, Lorenz S, Rust A, de Bono JS, Yap TA, Tutt ANJ, Lord CJ. Pettitt SJ, et al. Among authors: brough r. Oncogene. 2023 Sep;42(36):2701-2709. doi: 10.1038/s41388-023-02782-8. Epub 2023 Jul 25. Oncogene. 2023. PMID: 37491606 Free PMC article.
Searching for synthetic lethality in cancer.
Brough R, Frankum JR, Costa-Cabral S, Lord CJ, Ashworth A. Brough R, et al. Curr Opin Genet Dev. 2011 Feb;21(1):34-41. doi: 10.1016/j.gde.2010.10.009. Epub 2011 Jan 20. Curr Opin Genet Dev. 2011. PMID: 21255997 Review.
Defective ALC1 nucleosome remodeling confers PARPi sensitization and synthetic lethality with HRD.
Hewitt G, Borel V, Segura-Bayona S, Takaki T, Ruis P, Bellelli R, Lehmann LC, Sommerova L, Vancevska A, Tomas-Loba A, Zhu K, Cooper C, Fugger K, Patel H, Goldstone R, Schneider-Luftman D, Herbert E, Stamp G, Brough R, Pettitt S, Lord CJ, West SC, Ahel I, Ahel D, Chapman JR, Deindl S, Boulton SJ. Hewitt G, et al. Among authors: brough r. Mol Cell. 2021 Feb 18;81(4):767-783.e11. doi: 10.1016/j.molcel.2020.12.006. Epub 2020 Dec 16. Mol Cell. 2021. PMID: 33333017 Free PMC article.
SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance.
Llorca-Cardenosa MJ, Aronson LI, Krastev DB, Nieminuszczy J, Alexander J, Song F, Dylewska M, Broderick R, Brough R, Zimmermann A, Zenke FT, Gurel B, Riisnaes R, Ferreira A, Roumeliotis T, Choudhary J, Pettitt SJ, de Bono J, Cervantes A, Haider S, Niedzwiedz W, Lord CJ, Chong IY. Llorca-Cardenosa MJ, et al. Among authors: brough r. Cancer Res. 2022 Nov 2;82(21):3962-3973. doi: 10.1158/0008-5472.CAN-21-4339. Cancer Res. 2022. PMID: 36273494 Free PMC article.
98 results